Dominique Lesuisse

TL;DR: In this paper, novel derivatives of general formula (I) and their pharmaceutically acceptable salts as kinase inhibitor and their use for preparing pharmaceutical compositions for preventing or treating diseases resulting from abnormal kinase activity such as, for example, those involved in neurodegenerative diseases, Alzheimer's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease.

TL;DR: The results suggest that a screening approach using protein crystallography is particularly useful to identify universal fragments for the conserved hydrophilic recognition sites found in target families such as SH2 domains, phosphatases, kinases, proteases, and esterases.

TL;DR: In this paper, the products of formula (I) in which V represents a heterocyclic radical, as protein kinases inhibitors, were introduced. But this was not the case in this paper.

TL;DR: Results indicate that compounds that bind to the Src SH2 domain can inhibit Src activity in cells and inhibit osteoclast-mediated resorption.

TL;DR: A series of potent bis‐azaindole inhibitors of IGF1‐R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis, but the model was not validated by the co‐crystallization experiments with IGF 1‐R.